Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: A retrospective single-centre study

Aplastic anemia (AA), characterized by peripheral pancytopenia, bone marrow (BM) hypocellularity, and hematopoietic stem cell niche number impairment, is a potentially fatal disorder for which immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the principal interventions.1-3 According to the treatment guidelines, upfront HSCT from an HLA-matched sibling donor (MSD) is recommended for severe AA (SAA) patients younger than 35 years.4 If no MSD is available, horse anti-thymocyte globulin (ATG)-based IST is indicated, and allo-HSCT from an unrelated donor (URD) is considered to be the standard treatment after IST failure.

Source: Biology of Blood and Marrow Transplantation - March 25, 2019 Category: Hematology Authors: Yuping Zhang, Liangliang Wu, Wenjian Mo, Ming Zhou, Yumiao Li, Xiaowei Chen, Caixia Wang, Shiyi Pan, Shilin Xu, Wei Zhou, Ruiqing Zhou, Shunqing Wang Source Type: research